Peptide and Macrocycle Therapeutics

Peptide and macrocycle therapeutics comprise a rapidly expanding class of intermediate-sized pharmaceutical modalities (molecular weight MW ≈ 500 to 5,000 Da) that occupy the "middle chemical space" ("beyond Rule of Five" or bRo5 space) between classical orally bioavailable small molecules (MW < 500 Da, governed by Lipinski's rule of five) and large protein biologics such as monoclonal antibodies (MW ≈ 150,000 Da). Whereas small molecules excel at crossing cell membranes to bind deep, hydrophobic enzyme or receptor cavities (300–600 ų), and monoclonal antibodies bind flat extracellular surfaces with picomolar affinity but cannot cross plasma membranes, engineered peptides and macrocycles (cyclic molecules containing a ring of 12 or more covalently connected atoms) bridge both regimes.

More than 80 peptide and macrocyclic drugs have received global regulatory approval across endocrinology, oncology, infectious disease, and immunology—ranging from Frederick Banting and Charles Best's isolation of insulin (1921; 51 amino acids, MW = 5,808 Da) and the immunosuppressant cyclic peptide cyclosporine A (MW = 1,203 Da) to modern long-acting glucagon-like peptide-1 (GLP-1) receptor agonists (semaglutide and dual GIP/GLP-1 agonist tirzepatide) that transform the treatment of type 2 diabetes and obesity. Through backbone N-methylation, hydrocarbon stapling, fatty-acid albumin tethering, and mRNA display screening of trillions of non-canonical macrocycles, medicinal chemists have overcome the historical liabilities of native peptides: rapid proteolytic degradation and negligible oral bioavailability.

Conformational Pre-Organization and Entropy Reduction

Linear peptides and flexible acyclic chains exist in aqueous solution as vast ensembles of rapidly interconverting conformations. When an unconstrained linear peptide binds to its biological target, freezing its rotatable backbone dihedral angles (φ, ψ, ω) into a single bioactive geometry incurs a large unfavorable conformational entropy penalty (−*T*Δ*S*°_conf > 0) that weakens net binding affinity (Δ*G*° = Δ*H*° − *T*Δ*S*°).

Macrocyclization—closing a linear chain into a 12- to 30+-membered ring via head-to-tail amide condensation, disulfide bridges (–S–S–), thioether linkages (–S–CH2–), ring-closing olefin metathesis (RCM), or copper-catalyzed azide–alkyne cycloaddition—restricts the conformational degrees of freedom of the unbound molecule in solution. When the macrocycle ring size and stereochemistry are tuned to pre-organize the ligand into its target-bound conformation, macrocyclization reduces the entropic penalty of binding by 1.5 to 3.0 kcal·mol⁻¹, translating into a 10- to 100-fold increase in binding affinity (K_d) and higher selectivity over off-target proteins. This thermodynamic principle is exploited not only in cyclic peptides, but also in synthetic small-molecule kinase macrocycles such as the third-generation ALK/ROS1 inhibitor lorlatinib (MW = 406 Da), where cyclizing an acyclic diaryl precursor into a rigid 12-membered macrocycle enhanced blood–brain barrier penetration (reducing P-gp efflux) and boosted potency against resistance mutations by >40-fold.

Chameleonic Passive Permeability: The Cyclosporine A Prototype

Although macrocyclic peptides violate Lipinski's cutoffs (MW > 500 Da, hydrogen-bond acceptors > 10, polar surface area TPSA > 140 Ų), a subset of natural and synthetic macrocycles achieves 25%–50% oral bioavailability through "molecular chameleonicity"—the ability to dynamically alter conformation and exposed polarity in response to solvent dielectric constant (ε).

The archetype of chameleonic behavior is the fungal undecapeptide cyclosporine A (MW = 1,203 Da, 11 amino acids), which achieves ~30% oral bioavailability despite having 11 amide bonds. Two structural features enable cyclosporine A to cross the hydrophobic interior of intestinal lipid bilayers (ε ≈ 2):

1. Backbone N-Methylation: Seven of its eleven amide nitrogens are methylated (–CON(CH3)–), removing seven strong hydrogen-bond donors that would otherwise require ~4–5 kcal·mol⁻¹ each to desolvate from water.
2. Dynamic Intramolecular Hydrogen Bonding: In apolar lipid membrane environments, the remaining four unmethylated amide –NH donors fold inward to form four transannular intramolecular hydrogen bonds with backbone carbonyl oxygens, shielding the polar peptide backbone inside the core while projecting aliphatic side chains (leucine, valine, MeBmt) outward into the lipid tails. Once cyclosporine A emerges into the aqueous cytoplasm (ε ≈ 80), it unfolds into an open conformation that exposes its polar groups to bind cyclophilin A and inhibit calcineurin.

Resisting Proteolysis: D-Amino Acids, Aib, and Hydrocarbon Stapling

Unmodified endogenous peptide hormones (such as native GLP-1[7–36], somatostatin, or gonadotropin-releasing hormone) exhibit plasma half-lives (t_1/2) of only 1.5 to 5 minutes in humans because they are rapidly cleaved by plasma and endothelial exopeptidases (aminopeptidases and carboxypeptidases) and endopeptidases (such as dipeptidyl peptidase-4 [DPP-4] and neutral endopeptidase NEP) and are cleared by renal glomerular filtration (which filters molecules below ~30–50 kDa). Medicinal chemists stabilize therapeutic peptides through four principal modifications:

• D-Amino Acid and α,α-Disubstituted Amino Acid Substitution: Proteases evolve stereospecific active sites that recognize L-amino acids. Replacing cleavage-site residues with D-amino acids or achiral α-aminoisobutyric acid (Aib, or α-methylalanine) blocks enzymatic proteolysis. For example, DPP-4 inactivates native GLP-1 within 2 minutes by cleaving the amide bond after Ala8; substituting Ala8 with Aib8 in semaglutide and tirzepatide abolishes DPP-4 proteolysis.
• Hydrocarbon-Stapled α-Helical Peptides: Pioneered by Gregory Verdine and Loren Walensky, peptide stapling incorporates two α-methyl, α-alkenyl non-natural amino acids at positions i and i + 4 (one helical turn) or i and i + 7 (two helical turns) along a peptide chain, followed by ruthenium-catalyzed Grubbs ring-closing olefin metathesis to form an all-hydrocarbon covalent brace. The hydrocarbon staple locks the peptide into a rigid α-helix, shields the amide backbone from proteases, and enables energy-dependent cellular uptake to disrupt intracellular protein–protein interactions such as MDM2/MDMX–p53 (sulanemadlin / ALRN-6924).

Fatty-Acid Acylation and Albumin Hitchhiking: From 2 Minutes to 7 Days

Eliminating DPP-4 proteolysis alone extends the half-life of a 3.5 kDa GLP-1 analog to only ~1–2 hours because the unbound peptide is rapidly filtered through renal glomeruli. To bypass renal filtration without fusing a bulky 50 kDa Fc domain, Lotte Bjerre Knudsen and colleagues at Novo Nordisk pioneered reversible fatty-acid albumin hitchhiking.

Human serum albumin (HSA, MW = 66.5 kDa) is the most abundant protein in plasma (~600 μM, or 40 g/L), exceeds the renal glomerular filtration cutoff, and exhibits a 19-day circulatory half-life due to pH-dependent salvage recycling by the neonatal Fc receptor (FcRn). In liraglutide, attaching a C₁₆ palmitoyl chain via a γ-L-glutamyl spacer to Lys26 promotes self-assembly into heptamers at the subcutaneous depot and reversible binding to fatty-acid binding sites on circulating albumin, extending human t_1/2 to 13 hours (once-daily dosing). In semaglutide, replacing the C₁₆ monoacid with a C₁₈ octadecanedioic diacid (whose terminal carboxylate forms an electrostatic salt bridge inside albumin's high-affinity fatty-acid pocket) linked through two hydrophilic oligo(ethylene glycol) (OEG) spacers increased albumin affinity by ~6-fold (>99% plasma bound) while Aib8 blocked DPP-4, extending the human half-life to ~165 hours (7 days) for once-weekly injection. Furthermore, co-formulating semaglutide with the permeation enhancer salcaprozate sodium (SNAC, 300 mg) locally buffers gastric pH to inhibit pepsin and transiently fluidizes gastric epithelial membranes, enabling the first oral GLP-1 peptide tablet. Similarly, Eli Lilly's dual GIP/GLP-1 receptor co-agonist tirzepatide uses two Aib residues (positions 2 and 13) and a C₂₀ eicosanedioic diacid albumin binder to achieve a 5-day half-life and >20% mean clinical body-weight reduction.

RaPID mRNA Display and Phage-Displayed Bicycles

To discover de novo macrocycles against flat extracellular or intracellular targets that lack natural peptide ligands, Hiroaki Suga developed the RaPID (Random nonstandard Peptides Integrated Discovery) platform, which combines in vitro mRNA display with flexizyme-mediated genetic code reprogramming. Flexizymes charge tRNAs with non-canonical N-methylated amino acids, D-amino acids, and an N-terminal chloroacetylated D- or L-tyrosine/tryptophan initiator. Following ribosomal translation of a randomized mRNA library (~10¹²–10¹³ unique sequences), a downstream cysteine thiol spontaneously attacks the N-terminal chloroacetyl group to form a non-reducible thioether macrocycle covalently linked via puromycin to its encoding mRNA tag. Iterative affinity selection and medicinal chemistry optimization of RaPID hits yielded enlicitide decanoate (MK-0616), a tricyclic peptide (MW = 1,616 Da) that binds the flat LDL-receptor interface of PCSK9 with picomolar affinity (K_i ≈ 2 pM) and lowers human LDL cholesterol by ~60% following once-daily oral dosing.

How does macrocyclization increase the binding affinity of a peptide or small molecule?

An unconstrained linear molecule adopts many random conformations in water and must lose conformational entropy (−*T*Δ*S*°_conf) when locked into a single shape inside a protein pocket. Closing the linear chain into a macrocycle pre-organizes the unbound molecule into a shape close to its bioactive conformation, reducing the entropic penalty of binding by 1.5 to 3.0 kcal·mol⁻¹ and boosting binding affinity by 10- to 100-fold while shielding the backbone from proteases.

How can cyclosporine A cross cell membranes orally despite violating Lipinski's Rule of Five?

Cyclosporine A (MW = 1,203 Da) behaves as a "molecular chameleon." Seven of its eleven amide bonds are N-methylated, eliminating seven hydrogen-bond donors. When entering the nonpolar lipid core of an intestinal cell membrane, its four remaining amide NH groups fold inward to form four intramolecular hydrogen bonds with backbone carbonyls, hiding its polarity to diffuse across the membrane before unfolding again in the aqueous cytosol.

How was the half-life of GLP-1 extended from 2 minutes in native hormone to 7 days in semaglutide?

Native GLP-1 is cleaved within 2 minutes by the enzyme DPP-4 at Ala8 and rapidly filtered by the kidneys. Semaglutide replaces Ala8 with the non-natural amino acid α-aminoisobutyric acid (Aib8) to block DPP-4 cleavage, and attaches a C₁₈ diacid fatty chain via a hydrophilic linker to Lys26. This C₁₈ diacid binds reversibly to >99% of circulating human serum albumin, shielding the peptide from renal filtration and extending its human half-life to ~165 hours (7 days).

1. Vinogradov, A. A., Yin, Y., & Suga, H. (2019). "Macrocyclic peptides as drug candidates: recent progress and remaining challenges." Journal of the American Chemical Society, 141(10), 4167–4181. https://doi.org/10.1021/jacs.8b13178
2. Lau, J., Bloch, P., Schäffer, L., et al. (2015). "Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide." Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
3. Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021). "Trends in peptide drug discovery." Nature Reviews Drug Discovery, 20(4), 309–325. https://doi.org/10.1038/s41573-020-00135-8
4. Walensky, L. D., & Bird, G. H. (2014). "Hydrocarbon-stapled peptides: principles, practice, and progress." Journal of Medicinal Chemistry, 57(15), 6275–6288. https://doi.org/10.1021/jm4011675